Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Caris Life SciencesCAI -0.89%11 Buyback Yield % is -12.04 as of Jul. 26, 2026. GuruFocus rates CAI with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 738 Biotechnology companies, Caris Life Sciences ranks worse than 54.47% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Caris Life Sciences Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Caris Life Sciences's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAI vs DNTH, MANE, TNGX: Buyback Yield % Comparison
For the Biotechnology subindustry, Caris Life Sciences's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caris Life Sciences Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Caris Life Sciences's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Caris Life Sciences's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caris Life Sciences (CAI) has a Buyback Yield % of -12.04 as of Jul. 26, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Caris Life Sciences and its competitors. According to the industry distribution chart, Caris Life Sciences ranks #402 out of 738 companies in the Biotechnology industry, placing it in the top 54.5%.
Is Caris Life Sciences' Buyback Yield % too high?
Caris Life Sciences' current Buyback Yield % is -12.04. Based on the distribution chart, Caris Life Sciences ranks #402 out of 738 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Caris Life Sciences has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Caris Life Sciences' Buyback Yield % compare to DNTH and MANE?
According to the Biotechnology industry distribution chart, Caris Life Sciences ranks #402 out of 738 companies for Buyback Yield %. This places Caris Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Caris Life Sciences and its competitors. Caris Life Sciences's current Buyback Yield % is -12.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caris Life Sciences stock overvalued right now?
Caris Life Sciences (CAI) has a current Buyback Yield % of -12.04. The current Buyback Yield % is -12.04. Caris Life Sciences' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Caris Life Sciences (CAI), the current Buyback Yield % is -12.04 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
11GF Score
Get the complete analysis for CAI
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI has been successfully added to your 
